Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02740270 | Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas | PHASE1 | COMPLETED | 92 | — | — | Jul 22, 2016 | Mar 3, 2020 | Feb 21, 2021 | 9 | United States, Canada +4 |
Dose Limiting Toxicities
Dose Limiting Toxicities
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | - |
| Arm B | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| GWN323 | DRUG | - |
| PDR001 | DRUG | - |
Inclusion Criteria: * Patients with metastatic and/or advanced solid tumors or lymphomas not amenable to curative treatment by surgery. * Histologically documented advanced or metastatic solid tumors or lymphomas * Must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |